Difference between revisions of "Team:UCSC/Project"

 
(153 intermediate revisions by 3 users not shown)
Line 1: Line 1:
 
{{UCSC-Header}}
 
{{UCSC-Header}}
 
 
<html>
 
<html>
 
 
<style>
 
<style>
  
.pageflow {
+
.metabolic-pathway {
   margin-right: 0px;
+
   margin: auto;
  margin-left: 0px;
+
  margin-top:30px;
+
 
   background: honeydew;
 
   background: honeydew;
 +
  width: 100%;
 
}
 
}
  
 
h1 {
 
h1 {
   font-family: 'Objektiv-mk1' !important;
+
   font-family: 'objektiv-mk1'!important;
 +
  font-size: 300%; /*!important*/
 
   font-weight: 300 !important;
 
   font-weight: 300 !important;
  font-size: 400%;
+
    width: 90%;
 
}
 
}
  
 
h2 {
 
h2 {
   font-family: 'Objektiv-mk1' !important;
+
   font-family: 'objektiv-mk1' !important;
        font-family: 'Objektiv-mk1' !important;
+
        font-weight: 300 !important;
+
 
   font-size: 200%;
 
   font-size: 200%;
 +
  font-weight: 300;
 +
}
 +
 +
h3 {
 +
  font-family: 'objektiv-mk1' !important;
 +
  font-size: 120%;
 +
  font-weight: 200;
 
}
 
}
  
Line 31: Line 34:
 
.proj-button {
 
.proj-button {
 
     position: relative;
 
     position: relative;
     width: 10%;
+
     width: 25%;
 +
    text-decoration: none !important;
 
}
 
}
  
Line 37: Line 41:
 
   opacity: 1;
 
   opacity: 1;
 
   display: inline-block;
 
   display: inline-block;
   width: 16%;
+
   width: 19%;
 +
  height: auto;
 +
  transition: .5s ease;
 +
  backface-visibility: hidden;
 +
}
 +
 
 +
.proj-button-image-solo {
 +
  opacity: 1;
 +
  display: inline-block;
 +
  width: 65%;
 
   height: auto;
 
   height: auto;
 
   transition: .5s ease;
 
   transition: .5s ease;
Line 52: Line 65:
 
   transform: translate(-50%, -50%);
 
   transform: translate(-50%, -50%);
 
   -ms-transform: translate(-50%, -50%)
 
   -ms-transform: translate(-50%, -50%)
 +
}
 +
 +
.overlap-button-text {
 +
  background-color: transparent;
 +
  color: black;
 +
  font-size: 20px;
 +
  font-family: "Objektiv-mk1" !important;
 +
  font-weight: 400 !important;
 +
  padding: 16px 32px;
 
}
 
}
  
 
.proj-button:hover .proj-button-image {
 
.proj-button:hover .proj-button-image {
 +
  opacity: 0.3;
 +
}
 +
 +
.proj-button:hover .proj-button-image-solo {
 
   opacity: 0.3;
 
   opacity: 0.3;
 
}
 
}
Line 69: Line 95:
 
}
 
}
  
.pagagraph {
+
.paragraph-left {
   font-family: 'Objektiv-mk1' !important;
+
   font-family: 'objektiv-mk1' !important;
 
+
  font-size: 18px;
 +
  text-align: left;
 +
  vertical-align: middle;
 
}
 
}
  
 
p {
 
p {
   font-family: 'Objektiv-mk1' !important;
+
   font-family: 'objektiv-mk1' !important;
  margin-left: 200px !important;
+
/*  margin-left: 200px !important;
   margin-right: 200px !important;
+
   margin-right: 200px !important;*/
 
   font-size: large !important;
 
   font-size: large !important;
 
}
 
}
  
 
.firstword {
 
.firstword {
   font-family: 'Objektiv-mk1' !important;
+
   font-family: 'objektiv-mk1' !important;
   font-size: 100px;
+
   font-size: 65px;
 +
}
 +
.quote {
 +
  font-family: 'objektiv-mk1' !important;
 +
  font-style: italic !important;
 +
  font-size: 28px;
 +
  line-height: 130%;
 +
}
 +
 
 +
.quote-person {
 +
  font-family: 'objektiv-mk1' !important;
 +
  font-size: 22px;
 +
  width: 100% !important;
 +
  text-align: right !important;
 +
  padding-right: 80px !important;
 
}
 
}
  
 
.titleimg {
 
.titleimg {
 
   vertical-align: middle;
 
   vertical-align: middle;
 +
  width: 15%;
 
}
 
}
  
 
.titlebox {
 
.titlebox {
   margin-left: 200px !important;
+
   margin-left: 0px !important;
 +
}
 +
 
 +
.reference-list {
 +
  font-family: 'objektiv-mk1';
 +
  font-size: 12px;
 +
  text-align: left;
 +
  list-style-type: none;
 +
  line-height: 100%;
 +
  margin-bottom: 80px;
 +
}
 +
 
 +
.reference-italic {
 +
  font-family: 'objektiv-mk1';
 +
  font-size: 12px;
 +
  font-style: italic;
 +
}
 +
 
 +
figcaption {
 +
  font-family: 'objektiv-mk1';
 +
  font-style: italic;
 +
  font-size: 13px;
 +
}
 +
 
 +
 
 +
@media (min-width: 1144px) {
 +
  .container {
 +
      width: 80% !important;
 +
    }
 +
 
 +
  .text-container {
 +
    width: 60%;
 +
    padding-left: 30px;
 +
    padding-right: 30px;
 +
  }
 +
 
 +
  .titlebox {
 +
    width: 80%;
 +
  }
 +
 
 +
  figcaption {
 +
    font-size: 16px;
 +
  }
 
}
 
}
  
@media (max-width: 1086px) {
+
@media (max-width: 1144px) {
  
 
     .titlebox {
 
     .titlebox {
Line 101: Line 186:
  
 
   p {
 
   p {
     font-family: 'Objektiv-mk1' !important;
+
     font-family: 'objektiv-mk1' !important;
     margin-left: 20px !important;
+
     margin-left: 10px !important;
     margin-right: 20px !important;
+
     margin-right: 10px !important;
 
     font-size: medium !important;
 
     font-size: medium !important;
 +
  }
 +
 
 +
  .quote {
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-style: italic !important;
 +
    font-size: 26px;
 +
  }
 +
 +
  .quote-person {
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-size: 20px;
 +
    width: 100%;
 +
    text-align: right;
 +
    padding-right: 80px !important;
 +
  }
 +
 +
  .metabolic-pathway {
 +
      margin: auto;
 +
      background: honeydew;
 +
      width: 100%;
 +
  }
 +
 +
  .container {
 +
    width: 70% !important;
 +
    padding-left: 0px !important;
 +
    padding-right: 0px !important;
 +
  }
 +
 +
  .text-container {
 +
    width: 80%;
 +
    padding-left: 0px;
 +
    padding-right: 0px;
 +
  }
 +
 +
  figcaption {
 +
    font-size: 14px;
 
   }
 
   }
 +
}
 +
 +
@media (max-width: 992px) {
 +
  .proj-button-image-solo {
 +
      opacity: 1;
 +
      display: inline-block;
 +
      width: 30%;
 +
      height: auto;
 +
      transition: .5s ease;
 +
      backface-visibility: hidden;
 +
    }
 
}
 
}
  
Line 112: Line 244:
 
       opacity: 1;
 
       opacity: 1;
 
       display: inline-block;
 
       display: inline-block;
       width: 40%;
+
       width: 32%;
 +
      height: auto;
 +
      transition: .5s ease;
 +
      backface-visibility: hidden;
 +
    }
 +
 
 +
    .proj-button-image-solo {
 +
      opacity: 1;
 +
      display: inline-block;
 +
      width: 35%;
 
       height: auto;
 
       height: auto;
 
       transition: .5s ease;
 
       transition: .5s ease;
Line 120: Line 261:
 
     .proj-button-desc {
 
     .proj-button-desc {
 
       transition: .5s ease;
 
       transition: .5s ease;
       opacity: 1;
+
       opacity: 0;
 
       position: absolute;
 
       position: absolute;
 
       top: 100%;
 
       top: 100%;
Line 126: Line 267:
 
       transform: translate(-50%, -50%);
 
       transform: translate(-50%, -50%);
 
       -ms-transform: translate(-50%, -50%)
 
       -ms-transform: translate(-50%, -50%)
 +
  }
 +
 +
  .overlap-button-text {
 +
    background-color: rgba(94, 94, 94, 0.0);
 +
    border-radius: 60px;
 +
    color: white;
 
   }
 
   }
  
 
   h1 {
 
   h1 {
       font-family: 'Quicksand'; /*!important*/
+
       font-family: 'objektiv-mk1'; /*!important*/
       font-size: 250%; /*!important*/
+
       font-size: 220%; /*!important*/
 +
      width: 80%;
 
   }
 
   }
  
  h2 {
+
    h2 {
       font-family: 'Quicksand'; /*!important*/
+
       font-family: 'objektiv-mk1'; /*!important*/
 
       font-size: 20px; /*!important*/
 
       font-size: 20px; /*!important*/
 +
  }
 +
 
 +
  .quote {
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-style: italic !important;
 +
    font-size: 20px;
 
   }
 
   }
  
 +
  .quote-person {
 +
    width: 100%;
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-size: 16px;
 +
    text-align: right !important;
 +
    padding-right: 20px !important;
 +
  }
 +
 +
  .text-container {
 +
    width: 82%;
 +
    padding-left: 0px;
 +
    padding-right: 0px;
 +
  }
 +
 +
  figcaption {
 +
    font-size: 14px;
 +
    line-height: 140%;
 +
  }
 +
 +
  .reference-list {
 +
    font-family: 'objektiv-mk1';
 +
    font-size: 12px;
 +
    text-align: left;
 +
    list-style-type: none;
 +
    line-height: 100%;
 +
    margin-bottom: 80px;
 +
    margin-right: -70px;
 +
    margin-left: -70px;
 +
  }
 +
}
 
/*  p {
 
/*  p {
 
     margin-left: 10px !important;
 
     margin-left: 10px !important;
Line 148: Line 332:
 
       opacity: 1;
 
       opacity: 1;
 
       display: inline-block;
 
       display: inline-block;
       width: 60%;
+
       width: 50%;
 +
      height: auto;
 +
      transition: .5s ease;
 +
      backface-visibility: hidden;
 +
    }
 +
 
 +
    .proj-button-image-solo {
 +
      opacity: 1;
 +
      display: inline-block;
 +
      width: 50%;
 
       height: auto;
 
       height: auto;
 
       transition: .5s ease;
 
       transition: .5s ease;
Line 156: Line 349:
 
     .proj-button-desc {
 
     .proj-button-desc {
 
       transition: .5s ease;
 
       transition: .5s ease;
       opacity: 1;
+
       opacity: 0;
 
       position: absolute;
 
       position: absolute;
 
       top: 100%;
 
       top: 100%;
Line 162: Line 355:
 
       transform: translate(-50%, -50%);
 
       transform: translate(-50%, -50%);
 
       -ms-transform: translate(-50%, -50%)
 
       -ms-transform: translate(-50%, -50%)
 +
  }
 +
 +
    .overlap-button-text {
 +
    background-color: rgba(94, 94, 94, 0.0);
 +
    border-radius: 60px;
 +
    color: white;
 +
    font-size: 12px;
 
   }
 
   }
  
 
   .firstword {
 
   .firstword {
     font-family: 'Quicksand' !important;
+
     font-family: 'objektiv-mk1' !important;
     font-size: 70px;
+
     font-size: 40px;
 
   }
 
   }
  
 
   .titleimg {
 
   .titleimg {
 
     vertical-align: middle;
 
     vertical-align: middle;
     width: 200px;
+
     width: 40%;
    height: 200px;
+
 
   }
 
   }
  
 
   p {
 
   p {
     font-family: 'Quicksand' !important;
+
     font-family: 'objektiv-mk1' !important;
     margin-left: 20px !important;
+
     margin-left: 10px !important;
     margin-right: 20px !important;
+
     margin-right: 10px !important;
 
     font-size: small !important;
 
     font-size: small !important;
 +
  }
 +
 +
  h1 {
 +
    font-size: 160%;
 +
  }
 +
 +
  .quote {
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-style: italic !important;
 +
    font-size: 17px;
 +
  }
 +
 +
  .quote-person {
 +
    width: 60% !important;
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-size: 12px;
 +
    text-align: right !important;
 +
    margin-right: -120px !important;
 +
  }
 +
 +
  .paragraph-left {
 +
    font-size: 13px;
 +
    line-height: 170%;
 +
  }
 +
 +
  .text-container {
 +
    width: 85%;
 +
    padding-left: 0px;
 +
    padding-right: 0px;
 +
  }
 +
 +
  .metabolic-pathway {
 +
      margin: auto;
 +
      background: honeydew;
 +
      width: 110%;
 +
      margin-left: -20px;
 +
      margin-right: -20px;
 +
  }
 +
 +
  figcaption {
 +
    font-size: 12px;
 +
    line-height: 130%;
 +
  }
 +
 +
  .reference-list {
 +
    font-family: 'objektiv-mk1';
 +
    font-size: 12px;
 +
    text-align: left;
 +
    list-style-type: none;
 +
    line-height: 100%;
 +
    margin-bottom: 80px;
 +
    margin-right: -50px;
 +
    margin-left: -50px;
 
   }
 
   }
 
}
 
}
  
 +
@media (max-width: 400px) {
 +
  .quote {
 +
    font-size: 15px;
 +
  }
 +
}
  
</style>
 
  
 +
</style>
  
 
<body>
 
<body>
Line 192: Line 449:
 
<br>
 
<br>
  
  <div class="titlebox">
+
<!--<div class="titlebox">
 
     <div class="row no-gutters justify-content-md-center">
 
     <div class="row no-gutters justify-content-md-center">
       <div class="col-md-4">
+
       <div class="col-sm-4">
         <!--<img class="titleimg" src="https://static.igem.org/mediawiki/2017/f/f9/3synechobuddies.png">-->
+
         <center>
         <img class="titleimg" src="https://static.igem.org/mediawiki/2017/5/59/Cyanobuddies.png">
+
          <img class="buddies" src="https://static.igem.org/mediawiki/2017/f/f9/3synechobuddies.png">
 +
         </center>
 
       </div>
 
       </div>
 
       <div class="col-md-6">
 
       <div class="col-md-6">
         <h1>Project Description</h1>
+
         <h1>PROJECT DESCRIPTION</h1>
 
       </div>
 
       </div>
 
     </div>
 
     </div>
  </div>
+
</div>-->
 +
 
 +
<center><img class='titleimg' src="https://static.igem.org/mediawiki/2017/3/36/Projectimg.png"></center>
 +
<h1>PROJECT DESCRIPTION</h1><br>
  
 
<br>
 
<br>
Line 213: Line 474:
 
   </div>-->
 
   </div>-->
  
   <div class="container">
+
   <div class="text-container">
     <p><span class="firstword">Much</span> of the world struggles with inadequate access to essential medicines and nutrition due to high pharmaceutical prices and unreliable distribution. Our solution is to decentralize production of these resources by engineering the robust cyanobacterium, Arthrospira platensis, to produce essential medicines and supplements self-sustainably, photosynthetically, and on-site at healthcare facilities. However, due to insufficient research into the genetics of A. platensis, we have undertaken two separate engineering endeavors in the metabolically similar Synechococcus elongatus PCC 7942 to produce acetaminophen and human-usable vitamin B12. The genes for acetaminophen production, 4ABH and nhoA, and those for B12 production, ssuE and bluB, have been transformed into PCC 7942 with the aim of method validation and subsequent migration to A. platensis, once a genetic system has been established. In addition, we are performing a whole genome sequencing of A. platensis UTEX 2340 to further this research and its potential medical applications.</p>
+
     <p><span class="firstword">Malnutrition</span> and inconsistent access to medicine are widespread global problems. While a great deal of progress has been made, micronutrient deficiency remains one of the leading causes of global disease burden, especially in non-industrialized regions<sup>[1]</sup>. Our project, <i>Bugs Without Borders</i>, aims to decentralize production of medical and dietary supplements by engineering the alkali photoautotroph, <i>Arthrospira platensis</i>, commonly referred to as Spirulina. <i>A. platensis</i> is the most quintessential organism for growth at “on-site” healthcare facilities due to its modest media cost, alkali growth conditions, and its inherent properties as a nutritional “superfood"<sup>[2]</sup>.</p>
  
     </div>
+
     <br>
 +
    <br>
 +
 
 +
    <center>
 +
      <img class="metabolic-pathway" src="https://static.igem.org/mediawiki/2017/5/59/Cyanobuddies.png">
 +
    </center>
 +
 
 +
    <br>
 +
    <br>
 +
 
 +
    <p>Based on information we gathered through correspondence with international healthcare professionals, acetaminophen and vitamin DMB B<sub>12</sub> (the form of vitamin B<sub>12</sub> that mammals can absorb) were selected from the World Health Organization (WHO)’s published Essential Medicines List as the most impactful products our photosynthetic “factories” could manufacture<sup>[3]</sup>.</p>
 +
 
 +
    <br>
 +
 
 +
    <p>The integration and performance of the genes in acetaminophen production, <i>4ABH</i> and <i>nhoA</i>, and those in vitamin DMB B<sub>12</sub> production, <i>ssuE</i> and <i>bluB</i>, were investigated in the model cyanobacteria, <i>Synechococcus elongatus</i> PCC 7942 with the aim of subsequent integration into <i>A. platensis</i> once a genetic system has been studied and established. An <i>in vivo</i> vitamin B<sub>12</sub> detection system was also optimized for <i>S. elongatus</i> and <i>E. coli</i> by altering the ribosome binding site on the B<sub>12</sub> riboswitch (part BBa_K1913011) and the <i>psbAI</i> (part BBa_K754000) promoter we used for its transcription. In addition, we aim to sequence the entire genome of <i>A. platensis</i> UTEX 2340 to further enable genetic research in this organism and its potential medical applications.</p>
 +
 
 +
  </div>
  
<br>
 
<br>
 
 
<br>
 
<br>
 
<br>
 
<br>
Line 227: Line 502:
 
<div class="row">
 
<div class="row">
 
   <a href="https://2017.igem.org/Team:UCSC/Acetaminophen" class="proj-button">
 
   <a href="https://2017.igem.org/Team:UCSC/Acetaminophen" class="proj-button">
       <img src="https://static.igem.org/mediawiki/2017/7/74/Ace_icon.png" class="proj-button-image">
+
       <img src="https://static.igem.org/mediawiki/2017/6/6c/Acetaminophenicon.png" class="proj-button-image">
 
       <div class="proj-button-desc">
 
       <div class="proj-button-desc">
         <div class="text">Acetaminophen</div>
+
         <div class="overlap-button-text">ACETAMINOPHEN</div>
 
       </div>
 
       </div>
 
   </a>
 
   </a>
  
 
   <a href="https://2017.igem.org/Team:UCSC/B-12" class="proj-button">
 
   <a href="https://2017.igem.org/Team:UCSC/B-12" class="proj-button">
       <img src="https://static.igem.org/mediawiki/2017/1/19/B12_icon.png" class="proj-button-image">
+
       <img src="https://static.igem.org/mediawiki/2017/a/a2/B12_flask_button.png" class="proj-button-image">
 
       <div class="proj-button-desc">
 
       <div class="proj-button-desc">
         <div class="text">Vitamin B-12</div>
+
         <div class="overlap-button-text">VITAMIN B<sub>12</sub></div>
 
       </div>
 
       </div>
 
   </a>
 
   </a>
  
   <a href="https://2017.igem.org/Team:UCSC/Bioreactor" class="proj-button">
+
   <a href="https://2017.igem.org/Team:UCSC/Model" class="proj-button">
       <img src="https://static.igem.org/mediawiki/2017/c/c4/Bioreactor_icon.png" class="proj-button-image">
+
       <img src="https://static.igem.org/mediawiki/2017/b/be/Modeling_button.png" class="proj-button-image">
 
       <div class="proj-button-desc">
 
       <div class="proj-button-desc">
         <div class="text">Bioreactor</div>
+
         <div class="overlap-button-text">MODELING</div>
 
       </div>
 
       </div>
 
   </a>
 
   </a>
 +
</div>
 +
<div class="row">
  
   <a href="https://2017.igem.org/Team:UCSC/Model" class="proj-button">
+
   <a href="https://2017.igem.org/Team:UCSC/Demonstrate" class="proj-button">
       <img src="https://static.igem.org/mediawiki/2017/d/d8/Modeling_icon.png" class="proj-button-image">
+
       <img src="https://static.igem.org/mediawiki/2017/a/ad/Resulticon.png" class="proj-button-image">
 
       <div class="proj-button-desc">
 
       <div class="proj-button-desc">
         <div class="text">Modeling</div>
+
         <div class="overlap-button-text">RESULTS</div>
 
       </div>
 
       </div>
 
   </a>
 
   </a>
  
   <a href="https://2017.igem.org/Team:UCSC/Results" class="proj-button">
+
   <a href="https://2017.igem.org/Team:UCSC/Target-Organism" class="proj-button">
       <img src="https://static.igem.org/mediawiki/2017/e/e6/Results_icon.png" class="proj-button-image">
+
       <img src="https://static.igem.org/mediawiki/2017/8/84/Spirulinaicon.png" class="proj-button-image">
 
       <div class="proj-button-desc">
 
       <div class="proj-button-desc">
         <div class="text">Results</div>
+
         <div class="overlap-button-text">TARGET ORGANISM</div>
 
       </div>
 
       </div>
 
   </a>
 
   </a>
  
</div>
+
  <a href="https://2017.igem.org/Team:UCSC/Part_Collection" class="proj-button">
 +
      <img src="https://static.igem.org/mediawiki/2017/9/9c/Parts_icon.png" class="proj-button-image">
 +
      <div class="proj-button-desc">
 +
        <div class="overlap-button-text">PARTS</div>
 +
      </div>
 +
  </a>
  
 +
<br>
 +
<br>
  
 +
<div class="container">
 +
    <div class="container">
 +
      <div class="reference-list">
 +
      <hr>
 +
        <li>[1] Taylor, D. W., & CIM, F. (2010). Pharmaceutical Access in Least Developed Countries: on-the-ground barriers and industry successes”. Cameron Institute, October.</li>
 +
        <li>[2] Spirulina Benefits: 7 Reasons to Try It (& 1 Major Caution) Wellness Mama. (n.d.). Retrieved October 26, 2017, from https://wellnessmama.com/4738/spirulina-benefits/</li>
 +
        <li>[3] World  Health  Organization, ed., <i>The  Selection  and  Use  of  Essential  Medicines: report  of  the WHO  Expert  Committee,  2007; (including  the  15th  model  list  of  essential  medicines</i>).  No. 946in WHO Technical Report Series, Geneva:  World Health Organization, 2007. OCLC: 254437808.</li>
 +
      </div>
 +
    </div>
 +
  </div>
 +
 +
<br>
 +
<br>
 +
 +
</div>
 
</center>
 
</center>
 
</div>
 
</div>
 
</body>
 
</body>
 
</html>
 
</html>
 
 
{{UCSC-Footer}}
 
{{UCSC-Footer}}

Latest revision as of 02:47, 2 November 2017


PROJECT DESCRIPTION




Malnutrition and inconsistent access to medicine are widespread global problems. While a great deal of progress has been made, micronutrient deficiency remains one of the leading causes of global disease burden, especially in non-industrialized regions[1]. Our project, Bugs Without Borders, aims to decentralize production of medical and dietary supplements by engineering the alkali photoautotroph, Arthrospira platensis, commonly referred to as Spirulina. A. platensis is the most quintessential organism for growth at “on-site” healthcare facilities due to its modest media cost, alkali growth conditions, and its inherent properties as a nutritional “superfood"[2].





Based on information we gathered through correspondence with international healthcare professionals, acetaminophen and vitamin DMB B12 (the form of vitamin B12 that mammals can absorb) were selected from the World Health Organization (WHO)’s published Essential Medicines List as the most impactful products our photosynthetic “factories” could manufacture[3].


The integration and performance of the genes in acetaminophen production, 4ABH and nhoA, and those in vitamin DMB B12 production, ssuE and bluB, were investigated in the model cyanobacteria, Synechococcus elongatus PCC 7942 with the aim of subsequent integration into A. platensis once a genetic system has been studied and established. An in vivo vitamin B12 detection system was also optimized for S. elongatus and E. coli by altering the ribosome binding site on the B12 riboswitch (part BBa_K1913011) and the psbAI (part BBa_K754000) promoter we used for its transcription. In addition, we aim to sequence the entire genome of A. platensis UTEX 2340 to further enable genetic research in this organism and its potential medical applications.



Click on an icon below to learn more about our project!

RESULTS
TARGET ORGANISM
PARTS



  • [1] Taylor, D. W., & CIM, F. (2010). Pharmaceutical Access in Least Developed Countries: on-the-ground barriers and industry successes”. Cameron Institute, October.
  • [2] Spirulina Benefits: 7 Reasons to Try It (& 1 Major Caution) Wellness Mama. (n.d.). Retrieved October 26, 2017, from https://wellnessmama.com/4738/spirulina-benefits/
  • [3] World Health Organization, ed., The Selection and Use of Essential Medicines: report of the WHO Expert Committee, 2007; (including the 15th model list of essential medicines). No. 946in WHO Technical Report Series, Geneva: World Health Organization, 2007. OCLC: 254437808.